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Unexplained recurrent spontaneous abortion
A B S T R A C T
Introduction: Immune imbalance at the maternal-fetal interface plays a fundamental role in the pathogenesis of
unexplained recurrent spontaneous abortion (URSA). Human amniotic epithelial cells (hAECs) possess preg-
nancy-friendly immunomodulatory effects. Here, we investigated how function of naive CD4+ T cells from URSA
patients is affected by hAECs.
Methods: Phenotypic characteristics of hAECs were determined by flow cytometry and their effect on pro-
liferation of allogeneic peripheral blood mononuclear cells (PBMCs) was evaluated by a BrdU cell proliferation
assay. Naive CD4+ T cells were isolated from 25 URSA patients and 5 healthy women and co-cultured with
hAECs. Immunomodulatory effects of hAECs on cytokines profile, proliferation of stimulated CD4+ T cells and
induction of regulatory T cells (Tregs) were assessed by ELISA and flow cytometry, respectively. Functional
competency of Tregs was evaluated in an allogeneic mixed lymphocyte reaction (MLR) system.
Results: hAECs did not elicit allogeneic proliferative responses of PBMCs, inhibited proliferation of naive CD4+ T
cells, induced production of Th2 and suppressed production of Th1 and Th17 cytokines. hAECs showed the
ability to induce differentiation of Tregs and production of transforming growth factor-beta1 (TGF-β1) and
interleukin-10 (IL-10). This ability was found to be superior in control subjects compared to URSA patients.
Indeed, Tregs generated in the presence of hAECs expressed higher levels of CTLA-4 compared to Tregs gen-
erated in their absence and restrained the proliferation of autologus PBMCs in MLR system.
Conclusion: Based on these findings, hAECs can be considered as one potential candidate in immunotherapy of
patients with URSA.
1. Introduction
Recurrent spontaneous abortion (RSA) is a common health problem
in women of reproductive age [1]. It is defined by the loss of three or
more consecutive pregnancies before the 20th week of gestation [2,3].
Although a variety of factors such as infections and abnormalities in-
cluding genetic, chromosomal, anatomic, immunologic, and endocrine
have been reported for their attribution into the disease, no identifiable
etiology was diagnosed in about 40–60% of patients [1,4,5]. This
condition is classified as unexplained recurrent spontaneous abortion
(URSA) [4]. It is associated with the failure of feto–maternal
immunologic tolerance [1]. Several studies established a number of
immunological defects in URSA women, including reduced number and
impaired function of regulatory T cells (Tregs) [6], Th1 versus Th2
dominancy [7], and increase in the number of Th17 cells and natural
killer (NK) cells in the peripheral blood and decidua [8,9].
Human amniotic epithelial cells (hAECs) are a potential source of
stem cells and are isolated from the amniotic membrane, the closest
layer to the fetus and in contact with the amniotic fluid [10–12]. In
addition to their capability to differentiate into several cells originating
from the ectoderm, endoderm, and mesoderm, such as myocytes, car-
diomyocytes, adipocytes, hepatocytes, pancreatic cells, and neural cells
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[11,13–15], several studies reported that hAECs exert im-
munomodulatory effects on innate and adaptive immune cells. It is
demonstrated that hAECs are able to extremely suppress B cell pro-
liferation and to inhibit macrophages and neutrophil migration [16,17].
Additionally, these cells can inhibit CD4+ T cell activation and decrease
proinflammatory cytokine production of CD4+ T cells [11,16]. Pre-
vious studies have provided evidence that immunoregulatory effects of
hAECs are mainly mediated through the production of im-
munosuppressive compounds such as transforming growth factor-beta
(TGF-β) and prostaglandin E2 (PGE2) [18,19].
Regarding the fact that hAECs exert immunosuppressive effects on
activation, proliferation, and cytokine production of different cells from
the immune system [11,20], we investigated whether hAECs can affect
the function of naive CD4+ T cells from URSA patients. Moreover, the
allogeneic effects of these cells were assessed to detect potential im-
mune-rejection reactions in case of clinical application.
2. Materials and methods
2.1. Ethics statement
The study was approved by the Ethics Committee of the Isfahan
University of Medical Sciences (protocol number: 394205) and per-
formed in accordance with the Declaration of Helsinki. All participants
provided informed consent before entering the study.
2.2. Study population
The study population comprised 25 URSA women (mean age of
28.33 years, range: 22–37 years) who were referred to a cell therapy
center in Isfahan, Iran, and 5 volunteer control women (mean age of
26.89, range: 20–31 years) without history of abortion who had at least
one live birth. The sampling from URSA patients was performed 1 week
before any immunotherapeutic modalities including immunotherapy
with paternal lymphocytes. The diagnosis of URSA was made after
excluding any verifiable causes including the detection of any uterus or
cervix abnormalities and chromosomal abnormality; infections due to
Chlamydia and Ureaplasma urealyticum; endocrine diseases such as hy-
perprolactinemia, hypothyroidism, hyperthyroidism, diabetes, and hy-
perandrogenemia; and diagnoses of congenital thrombophilia, anti-
phospholipid syndrome, and systemic lupus erythematosus. The URSA
patients whose partners had abnormal semen status were also excluded
according to World Health Organization criteria [21].
2.3. Isolation of hAECs
Full-term human placenta was obtained from 25 healthy women
with a normal singleton pregnancy undergoing uncomplicated elective
cesarean section. hAECs were isolated using a method as previously
described [22]. Briefly, amnion membrane was manually stripped from
the chorion and washed several times with 0.15M phosphate-buffered
saline (PBS) to remove the blood and cellular debris. The amnion was
digested with 0.05% trypsin (Gibco, USA) for 20min at 37 °C. The cells
from the first digestion were discarded to exclude the damaged cells.
The enzymatic digestion was followed twice for 30min at 37 °C. The
cells from the second and third digests were pooled and washed with
Hank's balanced salt solution (HBSS). The purity of cells obtained from
16 donors was determined by flow cytometry using the epithelial
marker cytokeratin (BioLegend, USA). Cells with a purity of ≥96%
were considered as hAECs.
2.4. hAEC culture
The isolated hAECs were cultured in 75-cm2 tissue culture flasks at a
density of 2.5× 105 cells/cm2 in Dulbecco's modified Eagle's medium/
Nutrient Mixture F-12 (DMEM/F12; Gibco, USA) supplemented with
10% fetal bovine serum (FBS; Gibco, USA) and 1% penicillin/strepto-
mycin (Sigma-Aldrich, USA). After 24 h of incubation at 37 °C, adhered
hAECs were dissociated by trypsin and plated at different numbers on
24-well plates for the next experiments.
2.5. Characterization of hAECs
Phenotypic characteristics of freshly isolated hAECs were de-
termined using flow cytometry. The cells (4–8× 105 cells/ml) were
stained with different antibodies (Table 1) or matched to isotype con-
trol IgG for 25min at 4 °C. The matched isotype control antibodies were
used as negative controls. Further, the samples were subjected to cy-
tokeratin staining as an intracellular epithelial marker after fixation and
permebilization of the cells according to the manufacturer's guidlines
(eBiosciences, USA). Data were acquired by a FACSCalibur system
(Becton Dickinson, San Jose, CA) and were analyzed using CellQuest
software (Becton Dickinson, San Jose, CA).
2.6. Assessment of the allogeneic effects of hAECs
To assess the possible allogeneic effects of hAECs, the isolated cells
were co-cultured with peripheral blood mononuclear cells (PBMCs) and
proliferative response was measured. The freshly isolated hAECs from
Table 1
Antibodies used for the determination of phenotypic characteristics of hAECs by Flow cytometry.
Fluorochrome/Antibody Isotype (Clone) Company (All from USA)
Alexa Fluor® 488 anti-Cytokeratin (pan reactive) Mouse IgG1, κ (C-11) BioLegend
FITC anti-human CD105 Mouse IgG1, κ (43A3) BioLegend
FITC anti-human CD90 Mouse IgG1, κ (5E10) BioLegend
FITC anti-human CD45 Mouse IgG1, κ (2D1) BioLegend
FITC anti-human CD14 Mouse IgG1, κ (63D3) BioLegend
FITC anti-human CD4 Mouse IgG1, κ (A161A1) BioLegend
FITC anti-human CD8a Mouse IgG1, κ (HIT8a) BioLegend
FITC anti-human CD38 Mouse IgG1, κ (HB-7) BioLegend
FITC anti-human CD3 Mouse IgG1, κ (HIT3a) BioLegend
PE anti-human SSEA-4 Mouse IgG3, κ (MC-813-70) BioLegend
PE anti-human CD133 Mouse IgG1, κ (Clone 7) BioLegend
FITC anti-human HLA-DR Mouse IgG2a, κ (G46-6) BD Biosciences
FITC anti-human CD34 Mouse IgG1, κ (8G12) BD Biosciences
PE anti-human CD56 Mouse IgG1, κ (B159) BD Biosciences
PE anti-human CD44 Mouse IgG2b, κ (515) BD Biosciences
PE anti-human CD9 Mouse IgG1, κ (M-L13) BD Biosciences
PE anti-human CD29 Mouse IgG2a, κ (HUTS-21) BD Biosciences
PE anti-human CD73 Mouse IgG1, κ (AD2) BD Biosciences
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the three amnion membranes were mixed and considered as a single
hAECs sample. In this experiment, four pools of hAECs obtained from
healthy pregnant women were prepared. PBMCs from four healthy
donors were isolated by Ficoll-Paque centrifugation. Afterwards,
2.5× 104 PBMCs from each donor were co-cultured with a single hAEC
sample at different ratios (1:1, 1:2, 1:3) in 96-well, flat-bottomed mi-
crotiter plates, at 37 °C with 5% CO2. All assays were performed in
duplicate. PBMCs stimulated with antihuman CD3/anti-CD28 anti-
bodies (1 μg/ml; Mabtech, Sweden) were used as a positive control, and
unstimulated PBMCs without any hAECs, as well as hAECs alone, were
used as negative controls. After 3 days, PBMC proliferation was assessed
using a bromodeoxyuridine (BrdU) cellular enzyme-linked im-
munosorbent assay (ELISA) kit according to the manufacturer's in-
structions (Abnova, USA).
2.7. Isolation of naive CD4+ T cells
PBMCs were obtained from heparinized whole blood of URSA and
control women by Ficoll-Paque centrifugation. Naive CD4+ T cells were
isolated from PBMCs by negative selection using magnetic beads
(Miltenyi Biotec, Germany). Subsequently, the isolated cells were
stained with picoerythrin/cyanin5 (PE/Cy5) antihuman CD4 and
fluorescein isothiocyanate (FITC) anti-human CD45RA antibodies. The
relevant isotype control antibodies served as the negative control. Cell
purity was analyzed using a FACSCalibur flow cytometer. The
CD4+CDRA + T cells were considered as naive CD4+ T cells. Cell
samples with> 90% purity were used in the following experiments. All
primary and matched isotype control antibodies were purchased from
BioLegend (USA).
2.8. T cell proliferation assay
Naive T cells were labeled with carboxyfluorescein succinimidyl ester
dye (CFSE) (BioLegend, USA) according to the manufacturer's protocol.
Briefly, naive CD4+ T cells (1×107) from URSA women were suspended
in 1ml of PBS, and 1 μl of CFSE (5mM/ml) was then added to make a
final concentration of 5 μM. After 15min of incubation in the dark at
37 °C, 2ml of ice-cold complete Roswell Park Memorial Institute (RPMI)
medium (Gibco, USA) was added to quench the staining. Thereafter,
different numbers of hAECs (4–40×104 cells/ml) were co-cultured at
different ratios (1:1, 1:2, 1:5, 1:10) with the CFSE-labeled naive T cells
(4×105 cells/ml) in 24-well plates and incubated at 37 °C with 5% CO2,
one set incubated for 3 days and another set for 6 days. Naive T cells were
stimulated with anti-CD3/anti-CD28 antibodies (1.5 μg/ml). Naive T cells
stimulated with anti-CD3/anti-CD28 antibodies without any hAECs were
used as the positive control, and unstimulated naive T cells without any
hAECs were used as the negative control. Proliferation of naive T cells was
assessed through fluorecent intensity measurement of CSFE dye using a
FACSCalibur flow cytometer.
2.9. Cytokine assay
To investigate the effects of hAECs on the cytokine profile of naive
CD4+ T cells, hAECs (4–40× 104 cells/ml) were co-cultured at dif-
ferent ratios (1:1, 1:2, 1:5, 1:10) with naive T cells (4× 105) from
URSA women in 24-well plates and stimulated with anti-CD3/anti-
CD28 (1.5 μg/ml) antibodies. The cells were then incubated at 37 °C
with 5% CO2. The co-cultured supernatants were collected after 3 and 6
days, and quantitative analysis of cytokines was performed using an
ELISA kit (Mabtech, Sweden). The following cytokines were measured:
IFN-γ, TNF-α, IL-4, and IL-17 A. The hAECs cultured without any naive
T cells and unstimulated naive T cells without any hAECs were con-
sidered as negative controls, and naive T cells stimulated with anti-
CD3/anti-CD28 antibodies served as the positive control. The limit of
detection of ELISA kits was 2 pg/ml for IFN-γ, TNF-α, and IL-17 A and
1 pg/ml for IL-4.
2.10. Differentiation of naive CD4+ T cells into tregs
Different numbers of hAECs (4–80× 104 cells/ml) were seeded in
24-well plates. Naive CD4+ T cells (4× 105 cells/ml) from control and
URSA women were then added to the wells to prepare hAEC-to-naive T
cell ratios of 2:1, 1:1, 1:2, 1:5, and 1:10. Naive T cells were stimulated
with anti-CD3/anti-CD28 antibodies (1.5 μg/ml) and incubated at 37 °C
with 5% CO2. Naive T cells cultured alone and stimulated with anti-
CD3/anti-CD28 antibodies served as control. After 6 days, T cells were
stained with PE antihuman CD25 and PE/Cy5 antihuman CD4 anti-
bodies for 20min at 4 °C. Fixation and permebilization were done using
True-Nuclear™ Transcription Factor Buffer Set and then subjected to
intracellular staining using Alexa Fluor 488 anti-human Foxp3 antibody
or the relevant isotype control antibody according to the manufacturer's
instructions (BioLegend, USA). To further evaluate the phenotypic
characteristics of Tregs differentiated in the presence of hAECs, five
samples from URSA women were simultaneously stained with PE anti-
CD25, Alexa Fluor 488 anti-FoxP3, and peridinin chlorophyll protein/
cyanin5.5(PerCP/Cy5.5) anti-human CD152 (CTLA-4) antibodies for
30min at 4 °C. All antibodies and buffers were purchased from
BioLegend (USA). Data were acquired using a FACSCalibur flow cyt-
ometer and analyzed using CellQuest software. In addition, the levels of
TGF-β1 and IL-10 in the supernatant of the co-cultures were measured
using an ELISA kit (Mabtech, Sweden) according to the manufacturer's
guidelines.
2.11. Functional characterization of tregs
To investigate the functional activity of Tregs generated in the
presence of hAECs, their effect on the suppression of allogeneic mixed
lymphocyte reaction (MLR) was assessed. Naive CD4+ T cells from five
URSA patients were cultured in the presence (hAEC-to-naive T cell ratio
of 2:1) or absence (control) of hAECs for 6 days as described above and
used as a source of Tregs in the allogeneic MLR system. To set the MLR
system up, allogeneic stimulator PBMCs were treated with Mitomycin C
(5 μg/ml, Sigma-Aldrich, USA) and were cultured (1× 105 cells/well)
in round-bottomed 96-well plates as stimulator cells. Responder PBMCs
were obtained from the same URSA patients, labeled with CFSE, and
added (1× 105 cells/well) to the wells containing stimulator cells.
Afterwards, different numbers of cells from Treg source (2–5×104)
were added to the wells to prepare the Tregs-to-autologous PBMC ratios
of 1:2 and 1:5. Responder PBMCs co-cultured with allogeneic stimulator
PBMCs served as the positive control, while responder PBMCs cultured
alone were considered as the negative control. All assays were per-
formed in duplicate. The cells were incubated at 37 °C with 5% CO2 for
3 days. The proliferation of responder PBMCs was then evaluated by
flow cytometry.
2.12. Statistical analysis
Data are represented as mean ± standard error of mean (SEM).
Statistical analyses were performed using GraphPad Prism 6 (GraphPad
software, San Diego, CA). One-way analysis of variance (ANOVA) and
unpaired t-tests were used to compare the groups with normal dis-
tribution and Mann–Whitney and Kruskal–Wallis tests in the case of
non-normal distribution. P value < 0.05 was considered statistically
significant.
3. Results
3.1. hAECs show some variations in their phenotypic characteristics
To determine the phenotypic characteristics of hAECs, we assessed
the presence of some reported markers of these cells isolated from four
distinct amnion donors using flow cytometry. Our results showed that
the isolated hAECs from four amnion donors extensively expressed
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cytokeratin (an epithelial marker) and SSEA-4 (an embryonic stem cell
marker), whereas the cells did not express hematopoietic markers in-
cluding CD34, CD133, and CD45 and some of the mesenchymal stem
cell (MSC) markers (CD90, CD105), as expected (Table 2). In contrast to
some studies [11,19], hAECs from four donors expressed high level of
CD73, an MSC marker (Table 2). Regardless of donor, all cells were
negative for HLA-DR, CD38, CD3, CD4, and CD8 markers and expressed
very low level of CD56 marker (Table 2). It was also observed that all
hAECs expressed low level of integrin-β2 (CD29), an adhesion molecule
(Table 2). As shown in Table 2, hAECs isolated from different donors
showed a great variation in hyaluronic acid receptor (CD44), CD14, and
CD9 expression.
3.2. hAECs do not induce alloreactive responses
To evaluate allogeneic properties of hAECs, allogeneic PBMCs were
co-cultured with hAECs at different ratios and the proliferative response
of PBMCs was measured. As shown in Fig. 1, there was no statistically
significant difference in the proliferation of PBMCs co-cultured with
hAECs at different ratios and those cultured alone. As a positive control,
PBMCs stimulated with anti-CD3/anti-CD28 antibodies showed high
level of proliferation (Fig. 1).
3.3. hAECs suppress the proliferation of naive CD4+ T cells from URSA
patients
To assess the possible suppressive effects of hAECs on the pro-
liferation of naive T cells, the proliferation of naive T cells stimulated
with anti-CD3/anti-CD28 antibodies in the presence or absence of
hAECs was measured. After 3 days, except for the 1:10 ratio, the pro-
liferation of activated T cells were significantly suppressed compared to
activated T cells cultured alone (p < 0.05–0.01, Fig. 2A and C). The
same trend was also observed for 6-day culture except that the pro-
liferation of naïve T cells co-cultured with hAECs at the 1:10 ratio was
also inhibited (p < 0.05–0.001, Fig. 2B and D).
3.4. hAECs exert immunomodulatory effects on the cytokine profile of naive
CD4+ T cells from URSA patients
Having considered that cytokines play an important role in preg-
nancy outcome, we evaluated immunomodulatory effects of hAECs on
cytokine profile of naive T cells. As shown in Fig. 3A–D, a statistically
significant reduction in the levels of IFN-γ and IL-17 A was observed at
all hAEC-to-naive T cell ratios after 3 and 6 days of co-culture
(p < 0.05–0.0001). Moreover, the level of IL-4 was significantly higher
at all hAEC-to-naive T cell ratios after 3 days (p < 0.01–0.0001,
Fig. 3E). This significant increase in IL-4 level was not observed on day
6 (Fig. 3F). Despite the changes in the levels of IFN-γ, IL-4, and IL-17 A,
no statistically significant difference was observed in the TNF-α level
(Fig. 3G and H).
3.5. hAECs induce differentiation of naive CD4+ T cells into
CD25 + Foxp3+ CTLA-4+Tregs
As Tregs favor pregnancy success, we evaluated whether hAECs can
induce the production of Tregs from naive CD4+ T cells of URSA and
control women. Our results showed that in both URSA patients
(p < 0.0001) and normal controls (p < 0.001–0.0001), hAECs sig-
nificantly induced the production of Tregs at all ratios (Fig. 4A and B).
Interestingly, hAECs induced the production of significantly more Tregs
in control subjects compared to URSA patients at all ratios tested, with
the exception of the 1:10 ratio (p < 0.01–0.05, Fig. 4B). Our data also
revealed that Tregs differentiated in the presence of hAECs expressed
higher levels of CTLA-4 compared to Tregs differentiated in the absence
of hAECs (p < 0.0001, Fig. 5A, B and C).
The levels of TGF-β1 and IL-10, the main cytokines for Treg func-
tion, in the co-culture supernatants were also measured. As shown in
Fig. 5D and E, there was a statistically significant increase in the levels
of TGF-β1 and IL-10 in the co-culture system compared to control wells
(p < 0.0001). Although there was no statistically significant difference
between the levels of TGF-β1 in URSA patients and control women
(Fig. 5D), the level of IL-10 in control women was significantly higher
than that in URSA women (p < 0.01, Fig. 5E).
3.6. Tregs differentiated in the presence of hAECs suppress allogeneic MLR
The functional activity of Tregs differentiated in the presence of
hAECs was assessed in an allogeneic MLR system. As shown in Fig. 6A
and C, Tregs differentiated in the presence of hAECs inhibited MLR
assay when added to the wells at all ratios (p < 0.05–0.01), whereas
such an inhibitory effect was not observed for Tregs differentiated in
Table 2
Phenotypic characterization of hAECs.
Marker Donor 1 Donor 2 Donor 3 Donor 4
Pan Cytokeratin ++++ ++++ ++++ ++++
CD73 +++ +++ +++ +++
SSEA-4 +++ +++ +++ +++
CD133 – – – –
CD90 – – – –
CD105 – – – –
CD34 – – – –
CD45 – – – –
CD9 ++ – + –
CD38 – – – –
CD29 + + + +
CD44 – + + ++
HLA-DR – – – –
CD56 −/+ −/+ −/+ −/+
CD14 + ++ – –
CD3 – – – –
CD4 – – – –
CD8 – – – –
-: No expression, −/+: very low expression (< 10%), +: low expression
(10–30%).
++: intermediate expression (30–60%), +++: high expression (60–90%).
++++: very high expression (> 90%).
Fig. 1. Allogeneic effects of hAECs on PBMCs from control subjects. PBMCs
were co-cultured with different numbers of hAECs for 3 days. The alloreactive
response of PBMCs was measured using a BrdU cellular ELISA kit (n=4).
PBMCs stimulated with anti-CD3/anti-CD28 antibodies were used as the posi-
tive control. All data are represented as mean ± SEM.
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the absence of hAECs (Fig. 6B and C). We also found that the pro-
liferation of responder cells in the wells containing Tregs obtained from
hAECs co-culture was significantly lower than that of cells containing
Tregs differentiated in the absence of hAECs (Fig. 6C, p < 0.05).
4. Discussion
hAECs are a type of stem cells that can be isolated from the amniotic
membrane [23]. Previous studies revealed that hAECs have potent
immunomodulatory characteristics [11,18]. In this study, we evaluated
the immunomodulatory effects of hAECs on naive CD4+ T cells from
women with URSA in which multiple defects in maternal im-
munological tolerance to the fetus have been proposed to be responsible
for miscarriage [1]. Our results showed that hAECs suppressed CD4+ T
cells proliferation, induced cytokines profile of Th2, and promoted the
differentiation of naive CD4+ T cells into Tregs.
URSA is one of the most frustrating problems in reproductive
medicine [24,25]. It is reported that in a large proportion of URSA
patients, abnormalities in cell-mediated immunity, such as increased
Th1-to-Th2 ratio, Tregs deficiency, and increased Th17 cell number,
were observed, which may lead to miscarriage [6–8]. Several ther-
apeutic approaches for URSA patients have been proposed to modulate
abnormal maternal immune responses such as paternal lymphocyte
immunotherapy and intravenous immunoglobulin (IVIG) therapy [26].
Although the results of some studies indicated that immunotherapy
with paternal lymphocytes and IVIG may be helpful in treatment of
URSA patients, the evidence is insufficient to support the efficacy of
these therapeutic approaches [26]. In addition, there are a number of
concerns regarding the side effects of these approaches such as trans-
fusion-related reactions, autoimmunity, and cancer [27,28]. hAECs,
which are cells with immunoregulatory effects, may be considered as a
potential candidate for immunotherapy of URSA women. Some unique
characteristics of these cells make them a suitable cell source in cell
therapy of URSA patients, such as a very low level of HLA-class I an-
tigen expression, absence of HLA-class II antigen, co-stimulatory mo-
lecules on their surface, and the possibility of their isolation in large
quantities without the need to expand them ex vivo [11,23,29]. In line
with this notion, our results demonstrated that hAECs did not express
HLA-DR and did not elicit allogeneic proliferative responses when co-
cultured with PMBCs. Accordingly, Liu et al. reported that these cells
did not stimulate xenogeneic proliferation of mouse splenocytes [18].
Indeed, hAECs do not express telomerase and might not be tumorigenic
upon transplantation [29]. These features alleviate such concerns as-
sociated with the application of other stem cell sources as
Fig. 2. Effect of hAECs on the proliferation of naive CD4+ T cells from URSA patients. Naive T cells were isolated from URSA patients and then co-cultured at
different ratios with hAECs; they were also stimulated with anti-CD3/anti-CD28 antibodies (n = 10). Unstimulated T cells and T cell stimulated with anti-CD3/anti-
CD28 antibodies cultured alone were considered as the positive control and negative control, respectively. The proliferation of the CSFE-labeled T cells was
monitored by flow cytometry after 3 days (A) and 6 days (B) and later analyzed (C and D). Each bar in C and D shows mean ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001.
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Fig. 3. Cytokine profile of naive CD4+ T cells from URSA patients after co-culture with hAECs in different ratios. Naive T cells from URSA patients were
stimulated with anti-CD3/anti-CD28 antibodies in the presence or absence of hAECs at different ratios for 3 and 6 days (n = 18). T cells cultured alone and
stimulated with anti-CD3/anti-CD28 antibodies were considered as the positive control. Unstimulated T cells cultured alone and hAECs cultured alone served as
negative controls. The levels of IFN-γ (A and B), IL-17 A (C and D), IL-4 (E and F), and TNF-α (G and H) were measured by an ELISA assay. All data are represented as
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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immunological rejection and tumor formation after transplantation
[29,30].
To assess potential variation in immunophenotype of hAECs from
different donors, which may potentially affect their therapeutic effi-
cacy, the expression of a wide range of surface and intracellular mar-
kers was evaluated. Our results showed that hAECs from different do-
nors had almost a similar phenotype in terms of the expression pattern
of markers attributed to epithelial cells (cytokeratin), embryonic stem
cells (SSEA-4), MSCs (CD105, CD73, and CD90), hematopoietic stem
cells (CD34), immune cells (HLA-DR, CD56, CD3, CD4, and CD8), and
adhesion molecules (CD29). Despite this considerable homogeneity
between different hAECs, there were differences in the levels of CD9,
CD14, and CD44. There is a noticeable inconsistency in the literature
regarding the expression of MSC markers and some other markers on
hAECs. Although there are reports pointing to the lack of CD73, CD90,
and CD105 expression on hAECs [19,31], there are reports indicating
the expression of these markers [11,32]. In this study, we observed thatFig. 4. (continued)
Fig. 5. Phenotypic characterization and cytokine profile of Tregs differentiated in the presence or absence of hAECs. Tregs differentiated in the presence
(hAEC-to-naive T cell ratio of 2:1) or absence (control) of hAECs were stained with anti-CD25, anti-Foxp3, and anti-CTLA-4 antibodies (n = 5). The percentage of
CTLA-4+ Tregs was monitored by flow cytometry on day 6 (A and B) and then analyzed (C). Gray-shaded histogram: Tregs differentiated in the presence or absence
of hAECs were stained with matched isotype control antibodies as negative controls. Black line: Tregs differentiated in the presence of hAECs were stained with anti-
CD25, anti-Foxp3, and anti-CTLA-4 antibodies. Blue line: Tregs differentiated in the absence of hAECs were stained with anti-CD25, anti-Foxp3, and anti-CTLA-4
antibodies. The levels of TGF-β1 and IL-10 in co-culture supernatants of hAECs with naive T cells from URSA women (n = 15) and control women (n = 5) were also
measured by ELISA on day 6 (D, E). Each bar in C, D and E shows mean ± SEM. **p < 0.01, ****p < 0.0001.
Fig. 4. Effect of hAECs on Tregs differentiation from naive CD4+ T cells. Different numbers of hAECs were co-cultured with naive CD4+ T cells from URSA
women (n = 15) and control women (n = 5). Naive T cells were stimulated with anti-CD3/anti-CD28 antibodies for 6 days. T cells stimulated with anti-CD3/anti-
CD28 antibodies without any hAECs were used as control. The percentage of Tregs was monitored by flow cytometry on day 6 (A) and then analyzed (B). Each bar in
B shows mean ± SEM. ***p < 0.001, ****p < 0.0001.
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hAECs isolated from different sources were negative for CD90 and
CD105, whereas they expressed a significant level of CD73. This dis-
crepancy could be attributed to cell isolation procedure, culture con-
dition, number of cell passage, and the time of delivery in which the
placenta samples were obtained [22,32–34]. For instance, the level of
HLA-G expression in preterm hAECs is less than that in term hAECs
[34].
In the next step, we evaluated immunomodulatory effects of hAECs
on the proliferation and differentiation of naive CD4+ T cells from
URSA patients. Our results showed that hAECs restrained naive CD4+ T
cells from cell division in a dose-dependent manner. Several lines of
evidence suggest that hAECs suppress the proliferation of T cells
through TGF-β1 and PGE2 production [18,19]. We also observed that
hAECs were capable of producing TGF-β1. In an effort to assess the
immunoregulatory effects of hAECs on Th1/Th2 cytokine profile, we
found a significant reduction in IFN-γ level at all tested hAECs to naive
T cells co-culture ratios after 3 and 6 days, which is consistent with in
vitro studies conducted on CD4+ T cells from healthy individuals [11].
An increase in the level of IL-4 was also observed after 3 days of co-
culture, but not after 6 days, which may be due to the instability and
quick degradation of this cytokine. Our results support previous studies
and indicate that immunotherapy with hAECs led to a shift from Th1-
type responses to Th2-type responses in an animal model of multiple
sclerosis and also to an improvement in disease course [11,18].
As it has been suggested that Th17 cells are harmful to the suc-
cessful pregnancy and the number of Th17 cells is higher in the per-
ipheral blood of URSA patients compared to the normal controls [8,35],
we next evaluated the impact of hAECs on the production of IL-17 from
naive CD4+ T cells in URSA women. Interestingly, hAECs caused a
significant decrease in IL-17 level after 3 and 6 days co-culture. The
same effect has also been reported after intraperitoneal injection of
hAECs to animals with experimental autoimmune encephalomyelitis
(EAE) [11].
Tregs play an important role in the maintenance of self-tolerance
and establishment of immunologic tolerance at the feto–maternal in-
terface [6,36,37]. Previous studies indicated that the percentage of
decidual Tregs was decreased in patients with URSA [6,38]. In the
current study, we showed that hAECs had the ability to induce differ-
entiation of naive CD4+ T cells toward Tregs in both URSA patients and
control women. Interestingly, our data revealed that differentiation of
naive CD4+ T cells into Tregs in the presence of hAECs occurred more
efficiently in control subjects compared to URSA women. This finding
was in line with our finding showing that supernatant of naive T cells/
hAECs co-cultures from control women contained significantly more
Fig. 6. Immunosuppressive effects of Tregs differentiated in the presence or absence of hAECs on autologous PBMCs from URSA patients. Autologous CSFE-
labeled PBMCs were co-cultured with heterologous PBMCs treated with Mitomycin C in an MLR assay. Different numbers of autologous Tregs differentiated in the
presence (hAEC-to-naive T cell ratio of 2:1) or absence (control) of hAECs were added to the MLR system (n = 5). Autologous PBMCs and heterologous PBMCs were
considered as responder (R) and stimulator (S) cells, respectively. The responder and stimulator cells co-cultured without autologous Tregs served as the positive
control (R + S), whereas the responder PBMCs cultured alone were considered as the negative control (R). The proliferation of the responder PBMCs was monitored
by flow cytometry on day 3 (A and B) and then analyzed (C). Each bar in C shows mean ± SEM. *p < 0.05, **p < 0.01.
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TGF-β1, which is needed for Treg differentiation. Indeed, the levels of
IL-10 and TGF-β1 were dramatically increased when naive T cells were
co-cultured with hAECs, thus indicating the supportive role of hAECs
for Treg induction. The ability of hAECs in inducing Tregs is consistent
with the finding from previous studies in which an increase in the
number of Tregs was observed in animals with EAE and fibrotic lung
injury following immunotherapy with hAECs [11,39]. In an effort to
determine the functionality of Tregs differentiated in the presence of
hAECs, we found the result contrary to that of control Tregs; these cells
were able to suppress the proliferation of autologous PBMCs from URSA
patients in an MLR assay. This finding may be due to altered im-
munophenotype of Tregs generated in the presence of hAECs, as we
showed that these cells expressed significantly higher level of CTLA-4
compared to that of the control Tregs. Notably, CTLA-4 was reported to
be responsible for all three characteristic Treg functions of suppression,
TCR hyposignaling, and anergy [40]. Indeed, a significant increase in
the number of Tregs differentiated in the presence of hAECs compared
to those differentiated in the absence of hAECs might also be re-
sponsible for their differential suppressive effect in the MLR system.
Overall, the results of this study provide evidence to show that
hAECs possess potent immunomodulatory effects on naive CD4+ T cells
from URSA patients, including suppressing cell proliferation, promoting
functional Tregs differentiation, skewing cytokine profile to Th2 pat-
tern, and inhibiting Th1 and Th17 cytokine production. Based on these
findings and also their partial inertness in eliciting alloreactive immune
responses, hAECs can be considered as one of the potential candidates
for the immunotherapy of patients with URSA. Further studies and
more information are required to determine whether hAECs can be
considered for clinical application in URSA.
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